AstraZeneca Reports Positive Results for Bladder Cancer Combo Treatment in Phase III Study

AstraZeneca reported that its Imfinzi combination therapy reduced the risk of death in a late-stage trial for small cell lung cancer, according to the company. The drug's effectiveness was demonstrated in a specific patient group, which may impact investor sentiment.

A Phase 3 trial of a combination treatment for advanced lung cancer by Amgen and AstraZeneca showed a 58% reduction in death risk, according to the companies.

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced death risk by 58% in extensive-stage small cell lung cancer patients, per phase 3 trial results. Median overall survival was 21.1 months vs. 12.7 months for Imfinzi alone. The combination also extended progression-free survival but had higher side effects. Results were presented at ESMO 2026 and published in NEJM.

Amgen's Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients, increasing median survival to 21.1 months. The study, presented at the European Society for Medical Oncology Congress, suggests potential for Imdelltra as a first-line maintenance therapy. Imdelltra reported $288M in Q2 2023 sales and $627M in 2025 global sales.

Amgen reported that a combination of its drug Imdelltra and AstraZeneca’s Imfinzi reduced death risk by 58% in a late-stage lung cancer trial. Median survival was 21.1 months for the combo group vs. 12.7 months for Imfinzi alone. Amgen's chief medical officer called the data potentially practice-changing. Imdelltra sales grew 115% year-over-year to $288M in Q2.

Amgen's Imdeltra combined with AstraZeneca's Imfinzi reduced death risk by 58% in late-stage small-cell lung cancer trials. Median survival increased from 12.7 to 21.1 months. Amgen and AstraZeneca are involved in the study, which may change treatment standards.